

New Views on HER2-Positive Breast Cancer

Low HER2, HER3 and Resistance CME

THURSDAY, MAY 2, 2019

REFRESHMENTS/REGISTRATION: 18:00 – 18:30 | **PRESENTATION:** 18:30 – 19:30

VENUE: MARITIM HOTEL BERLIN, BERLIN, GERMANY | **ROOM:** BERLIN HALL

Medscape
LIVE!



MODERATOR

Giuseppe Curigliano, MD, PhD
Professor/Director
European Institute of Oncology
University of Milan
Lombardia, Milano, Italy

PANELISTS

Fabrice André, MD, PhD
Professor/Chairman
Inserm Unit U981
Institut Gustave Roussy
Villejuif, France

Erika Hamilton, MD
Director
Breast & Gynecologic Program
Sarah Cannon Research Institute/
Tennessee Oncology
Nashville, Tennessee, United States

Sunil Verma, MD, MEd, FRCPC
Department Head
Department of Oncology Medical
Director
Tom Baker Cancer Center Medical
Lead
Calgary Cancer Project
Cumming School of Medicine
University of Calgary
Calgary, Alberta, Canada

AGENDA

18:00 – 18:30

Refreshments/Registration

18:30 – 18:40

Welcome and Introduction

Giuseppe Curigliano, MD, PhD

18:40 – 18:50

Taking the Molecular View:

Are Grey Areas Less Grey?

Sunil Verma, MD, MEd, FRCPC

18:50 – 19:00

Taking the Clinical View:

Who Is the Low HER2+ Patient?

Fabrice André, MD, PhD

19:00 – 19:10

Taking the Clinical View:

Who Is the HER2-Resistant Patient?

Giuseppe Curigliano, MD, PhD

19:10 – 19:20

Taking the Future View

Erika Hamilton, MD

19:10 – 19:20

Program Conclusion

Panel and Audience Question and Answer Session

Giuseppe Curigliano, MD, PhD



Refreshments
provided by
Medscape.